I think people need to look at the Good, Bad, and Ugly thing about investing in biotech. If you're not willing to accept all of them, this may not be where you should invest.
The good, tremendous stock price increases.
The bad, big drops in share price.
The ugly, you cannot predict the time to either of the above.
If you've determined that the science represented by what the company's developed is good, ideally great, science and that in the end you anticipate an approved product and substantial sales, realize you'll have to live with all the above, but in the end you'll be up substantially, and if you're like me, they'll be no end.
If a company gives you ten times your initial investment, but there is no reason to believe it will stop growing, why sell. Good companies that give ten times can very possibly do it all over again. For us today, ten times is $2.70, is there anyone who's a serious long here that doesn't believe $27.00 isn't possible.
It's my belief that if approval were limited to GBM, but all regulators approved DCVax-L the price would exceed $27.00, I don't believe it will take that long. Once that occurs, if DCVax-L is found effective in other cancers, how's $270.00 looking, I think it's very doable, in time.
We all need money in time, when you do, if you wish sell some NWBO, but think hard before you sell it all.
If before it moves up it makes another substantial move down, if it's not based on news that sour's you on the science, if you can, why not buy more and average down. That's biotech.
Gary
Bullish
Market Data 
Markets 
AI
